1999
DOI: 10.1023/a:1006293606710
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: A prospective pilot study was performed in order to assess the safety of treating recurrent malignant gliomas (MGs) with locally infused autologous tumor infiltrating lymphocytes (TILs) and recombinant interleukin-2 (rIL-2). Six patients were entered between June 27, 1994 and June 2, 1995 and followed until July 1, 1998. At surgery an Ommaya reservoir was placed for later infusion of TILs and rIL-2. Following surgery, autologous TILs were expanded in vitro in the presence of rIL-2 and infused on treatment days… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
47
0

Year Published

2004
2004
2017
2017

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 136 publications
(47 citation statements)
references
References 33 publications
0
47
0
Order By: Relevance
“…In its earlier renditions, ALT included the transfer of a variety of immune populations, not just T-cells. These have included peripheral blood mononuclear cells (PBMC) (21); lymphokine/mitogen-activated killer cells (LAK) (22); tumor-infiltrating lymphocytes (TIL) (23); and cytotoxic T-lymphocytes (CTL) (24, 25), administered either systemically (preclinical data supports tumor trafficking (26)) or into the tumor cavity. Targets have varied, and newer renditions have combined ALT with active vaccination (27) and/or prior myelosuppressive regimens (28) (NCT00693095), in efforts to promote survival and functional expansion of the transferred cells in vivo (active trials: NCT0114427, NCT01801852).…”
Section: Clinical Applications: Immunotherapeutic Approaches To Gbmmentioning
confidence: 99%
“…In its earlier renditions, ALT included the transfer of a variety of immune populations, not just T-cells. These have included peripheral blood mononuclear cells (PBMC) (21); lymphokine/mitogen-activated killer cells (LAK) (22); tumor-infiltrating lymphocytes (TIL) (23); and cytotoxic T-lymphocytes (CTL) (24, 25), administered either systemically (preclinical data supports tumor trafficking (26)) or into the tumor cavity. Targets have varied, and newer renditions have combined ALT with active vaccination (27) and/or prior myelosuppressive regimens (28) (NCT00693095), in efforts to promote survival and functional expansion of the transferred cells in vivo (active trials: NCT0114427, NCT01801852).…”
Section: Clinical Applications: Immunotherapeutic Approaches To Gbmmentioning
confidence: 99%
“…7 In total, 12 clinical trials were conducted using either LAK cells, or targeted T-cell therapies. [8][9][10][11][12][13][14][15][16][17][18] Quattrocci treated patients with gliomas with intra-lesional TIL and IL-2 19 leading to clinically relevant responses, i.e., one patient experienced a complete response, two patients a partial response and three patients progressed. Given the promising results from patients with melanoma and from patients with epithelial cancer, TIL therapy may also represent a viable option for the biological therapy of patients with glioma.…”
Section: Introductionmentioning
confidence: 99%
“…In a pilot study exclusively performed to date against patients with recurrent malignant gliomas that were treated with intratumoral infusion of ex vivo expanded autologous TILs with IL-2, one of six patients showed complete remission, two had partial responses, and three died of tumor progression [56]. The cytotoxic activity of TILs against autologous tumors in vitro was variously dependent on the patients and was not correlated with the clinical outcome in this study.…”
Section: Antitumor Immune Responses Of Effector Cellsmentioning
confidence: 79%
“…Major therapeutic limitation of these cells against tumors is that their lytic properties are not specifically directed against tumor cells. Autologous tumor cells were usually used as antigen source in ACT using LAK cells for malignant gliomas [5659]. …”
Section: Antitumor Immune Responses Of Effector Cellsmentioning
confidence: 99%